Achieving reliable and scalable lentiviral vector production

Thursday 14:26 IST / 16:56 +08 / 17:56 KST / 17:56 JST / 16:56 AWST / 21:56 NZDT

Sponsor

Achieving reliable and scalable lentiviral vector production

Developing stable lentiviral vector producer cell lines is a time-consuming and labor-intensive process, often taking a year or more to fully develop and characterize the cell line development platform. Due to the complexity of the work, many market-available systems ultimately fail to meet the needs of commercial manufacturing due to issues such as toxigenic titer, cell line stability, and culture adaptation.

EurekaBio has developed its proprietary EuLV® system, which can deliver stable LVV HEK293T producer cell lines in as short a time period as 5 months. The EuLV® system has irreplaceable advantages in terms of process reliability, scale-up capability, production cost, and virus product safety. The potential to achieve high-titer lentiviral vector manufacture using this platform will be explored in this webinar using a real-world case study.

Join us for a webinar on ways to address the pressing need for a reliable and scalable lentiviral vector manufacturing solution.

What is the EuLV stable producer cell line development platform
How to develop lentiviral vector producer cell lines using the EuLV platform
What is the EuBioX - an automated monoclonal screening platform
A real-world case study of a reliable and scalable LVV production workflow

Roy Liu

Chief Operation Officer, Eureka Biotechnology Co. Limited

Roy Bin Liu Business Development Director, EurekaBio. Mr Liu graduated from the Hong Kong University of Science and Technology with a Masters degree in Biotechnology. He previously worked in Bio-techne and InvivoGen. Mr Liu joined Eureka Bio in 2016, and has extensive knowledge of the cell and gene therapy industry, and is experienced in business development, project management, process development, cGMP etc.